Poorly differentiated cutaneous squamous cell carcinomas (cSCCs) are likely to be incompletely excised in peripheral and deep planes, despite adherence to the British Association of Dermatology-British Association of Plastic, Reconstructive and Aesthetic Surgery guidelines, reports a recent UK study.
The use of ipilimumab with stereotactic radiotherapy, either concurrently or sequentially, yields satisfactory outcomes with low toxicities in patients with metastatic cancer, according to the results of a phase II trial.
The once-weekly carfilzomib regimen of Kd70 mg/m2 for relapsed or refractory multiple myeloma (RRMM) is more favourable than the twice-weekly Kd27 mg/m2, as the former is associated with delayed symptom worsening and greater patient-reported convenience and satisfaction, according to a recent study.
In elderly adults with intermediate- or high-risk myelodysplastic syndromes or oligoblastic acute myeloid leukaemia, 5-azacytidine (5-AZA) may be an effective treatment option, a recent study has found.
Whole-pelvis radiotherapy (WPRT) improves biochemical recurrence-free survival (bRFS), but not distant metastasis-free survival (DMFS) and prostate cancer-specific survival (PCSS), in patients with Gleason grade group 5 prostate cancer (PCa) treated with either external-beam radiotherapy (EBRT) or EBRT with a brachytherapy boost (EBRT+BT), a recent study has found.
The combination obinutuzumab (Ga101) with the attenuated CHOP regimen (cyclophosphamide, doxorubicin, vincristine and prednisone; miniCHOP) is safe and effective for elderly patients with diffuse large B-cell lymphoma (DLBCL) who are unfit to receive the full-dose immunochemotherapy, a new study has found. However, the new regimen does not seem to be posed to challenge current treatment standards.
The Hedgehog pathway inhibitor vismodegib appears to be effective in the treatment of locally advanced periocular basal cell carcinoma (BCC), with adverse events (AEs) that are mostly manageable, as reported in a recent study.
Use of vedolizumab for inflammatory bowel disease (IBD) does not contribute to an increased incidence of malignancies, with data from the GEMINI LTS study showing that the rate is similar in groups of patients who received the 4- and 8-weekly infusion regimens.
Tivozanib as third- or fourth-line therapy improves progression-free survival (PFS) compared with sorafenib in patients with metastatic renal cell carcinoma (mRCC) who have received ≥2 previous systemic treatments, according to results of the phase III, randomized, controlled TIVO-3 trial.